uniQure falls on long-term Huntington's gene therapy data
uniQure's latest data drop for its gene therapy for Huntington's disease, under review in the US and UK, has spooked investors.
Novo turns to Hengrui for another oral obesity drug
Novo has agreed to pay up to $2.6 billion for rights to a weight-loss pill, developed by China's Hengrui Pharma, that could be dosed just once a week.
Mirum puts Hepcludex in its sights with hep D readout
Gilead's Hepcludex was the first drug to be cleared in the US for hepatitis D in May, but a potential rival from Mirum Pharma is already looming.
AZ takes stake in Summit Therapeutics in $2bn deal
AstraZeneca has taken a roughly 10% stake in Summit and signed a deal to test CLDN18.2-targeting sone-ve with PD-1xVEGF bispecific ivonescimab.
FDA clears first drug for MCT8 deficiency
Sweden's Egetis has won approval in the US for the first-ever treatment for people living with the ultra-rare genetic disease MCT8 deficiency.
Sales & Marketing
Digital
Market Access
Oncology
Patients
R&D
Partner Content
CPHI Milan 2026 showcases new Sustainability Summit
The first-time event will bring delegates together to discuss sustainability challenges
Industry leaders will address topics such as manufacturing t...
Pharmaceutical thought leaders gather at CPHI Milan 2026
5th Sustainability in Life Sciences Summit
Join the global sustainability community this November in Boston
CPHI Milan Leadership Summit returns for 2026
Senior pharma leaders will tackle resilience, policy, and industry transformation at CPHI Milan
Why Join The PM Society?
The professional organisation for people working in pharmaceutical marketing and healthcare communications, and why it's worth being part of.